Expert consensus of the Chinese Association for the Study of Pain on pain treatment with the transdermal patch
Ke Ma,Wei Jiang,Yun-Xia Wang,Lin Wang,Yan Lv,Jin-Feng Liu,Rong-Guo Liu,Hui Liu,Li-Zu Xiao,Dong-Ping Du,Li-Juan Lu,Xiao-Qiu Yang,Ling-Jie Xia,Dong Huang,Zhi-Jian Fu,Bao-Gan Peng,Yan-Qing Liu
DOI: https://doi.org/10.12998/wjcc.v9.i9.2110
2021-03-26
World Journal of Clinical Cases
Abstract:Chronic pain lasting more than 3 mo, or even several years can lead to disability. Treating chronic pain safely and effectively is a critical challenge faced by clinicians. Because administration of analgesics through oral, intravenous or intramuscular routes is not satisfactory, research toward percutaneous delivery has gained interest. The transdermal patch is one such percutaneous delivery system that can deliver drugs through the skin and capillaries at a certain rate to achieve a systemic or local therapeutic effect in the affected area. It has many advantages including ease of administration and hepatic first pass metabolism avoidance as well as controlling drug delivery, which reduces the dose frequency and side effects. If not required, then the patch can be removed from the skin immediately. The scopolamine patch was the first transdermal patch to be approved for the treatment of motion sickness by the Food and Drug Administration in 1979. From then on, the transdermal patch has been widely used to treat many diseases. To date, no guidelines or consensus are available on the use of analgesic drugs through transdermal delivery. The pain branch of the Chinese Medical Association, after meeting and discussing with experts and based on clinical evidence, developed a consensus for promoting and regulating standard use of transdermal patches containing analgesic drugs.
medicine, general & internal